Branched-chain amino acids and their metabolites decrease human and rat hepatic stellate cell activation.

ABSTRACT:

Background

End-stage liver diseases (ESLDs) are a significant global health challenge due to their high prevalence and severe health impacts. Despite the severe outcomes associated with ESLDs, therapeutic options remain limited. Targeting the activation of hepatic stellate cells (HSCs), key drivers of extracellular matrix accumulation during liver injury presents a novel therapeutic approach. In ESLDs patients, branched-chain amino acids (BCAAs, leucine, isoleucine and valine) levels are decreased, and supplementation has been proposed to attenuate liver fibrosis and improve regeneration. However, their effects on HSCs require further investigation.

Objective

To evaluate the efficacy of BCAAs and their metabolites, branched-chain α-keto acids (BCKAs), in modulating HSCs acti

SUBMITTER: Trillos-Almanza MC 

PROVIDER: S-EPMC11534903 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature